Maggie Gu is VP of Finance at Biosion, where she leads the company’s financial strategy and operations. She also serves on Biosion’s Board of Directors. Maggie has more than 20 years of finance leadership experience across multinational corporations and fast-growing biotech companies, including the last 17 years in biopharma across China, Asia Pacific and the US.
Before joining Biosion, Maggie was Global VP of Finance at LianBio. She helped the company through its US$325 million NASDAQ IPO and built a global finance platform spanning the US, Cayman, Asia Pacific and China. She played a key role in Bristol Myers Squibb’s US$350 million acquisition of LianBio’s mavacamten China rights, and later led the company through its strategic transition.
Prior to LianBio, Maggie was Associate Vice President of Finance at CStone Pharmaceuticals. Before that, she was Senior Finance Director at BeiGene and a member of its China Leadership Team. She built BeiGene’s integrated finance organization and supported the company’s NASDAQ follow-on offering and Hong Kong listing.
Earlier in her career, she spent eight years at Celgene, where she served as Finance Director and China CFO leading the finance organization. She helped launch Abraxane®, Revlimid® and Vidaza® in China and manage their lifecycles.
Maggie holds an MBA in Finance from the Rotman School of Management at the University of Toronto.